VERTEX PHARMACEUTICALS INC / MA Other Non-Current Liabilities
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Other Non-Current Liabilities of $1.26 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-08-04
- 2026-06-30: Other Liabilities, Noncurrent $1.26B.
- 2026-03-31: Other Liabilities, Noncurrent $1.26B.
- 2025-12-31: Other Liabilities, Noncurrent $1.27B.
- 2025-09-30: Other Liabilities, Noncurrent $1.23B.
| Period end | Other Liabilities, Noncurrent | Other Liabilities, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $1.26B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $1.26B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $1.27B 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $1.23B 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $1.20B 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $951.90M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $1.01B 10-K · filed 2026-02-13 | $901.80M 10-K · filed 2025-02-13 |
| 2024-09-30 | $933.30M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $876.80M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $853.60M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $877.70M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $869.30M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $759.30M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $726.50M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $685.80M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $115.70M 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $115.40M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $117.40M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $303.30M 10-K · filed 2023-02-10 | $116.80M 10-K · filed 2022-02-09 |
| 2021-09-30 | $108.47M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $107.69M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $106.26M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $108.40M 10-K · filed 2022-02-09 | $108.36M 10-K · filed 2021-02-11 |
| 2020-09-30 | $428.52M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $189.12M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $181.75M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $99.03M 10-K · filed 2021-02-11 | $183.32M 10-K · filed 2020-02-13 |
| 2019-09-30 | $7.64M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $8.01M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $6.00M 10-Q · filed 2019-05-01 | |
| 2019-01-01 | $70.23M 10-K · filed 2020-02-13 | $5.38M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $108.85M 10-K · filed 2020-02-13 | $26.28M 10-K · filed 2019-02-13 |
| 2018-09-30 | $26.30M 10-Q · filed 2018-10-25 | |
| 2018-06-30 | $25.59M 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $27.46M 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $27.77M 10-K · filed 2019-02-13 | $26.05M 10-K · filed 2018-02-15 |
| 2017-09-30 | $26.03M 10-Q · filed 2017-10-30 | |
| 2017-06-30 | $25.22M 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $28.47M 10-Q · filed 2017-04-28 | |
| 2016-12-31 | $28.70M 10-K · filed 2018-02-15 | $102.12M 10-K · filed 2017-02-23 |
| 2016-09-30 | $30.52M 10-Q · filed 2016-10-31 | |
| 2016-06-30 | $30.65M 10-Q · filed 2016-08-01 | |
| 2016-03-31 | $31.82M 10-Q · filed 2016-05-03 | |
| 2015-12-31 | $31.78M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $34.99M 10-Q · filed 2015-10-30 | |
| 2015-06-30 | $41.25M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $32.70M 10-Q · filed 2015-05-04 | |
| 2014-12-31 | $21.71M 10-K · filed 2016-02-16 | |
| 2014-09-30 | $15.95M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $15.67M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $12.03M 10-Q · filed 2014-05-05 | |
| 2013-12-31 | $11.59M 10-K · filed 2015-02-13 | |
| 2013-09-30 | $10.78M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $16.05M 10-Q · filed 2013-08-02 | |
| 2013-03-31 | $16.68M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $13.90M 10-K · filed 2014-02-11 | |
| 2012-09-30 | $28.74M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $28.01M 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $10.88M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $7.29M 10-K · filed 2013-03-01 | |
| 2011-09-30 | $7.85M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $6.23M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $2.27M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |